Press Releases Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Market Closed - Toronto S.E. Other stock markets 03:59:51 2024-04-29 pm EDT			5-day change	1st Jan Change
1.65 ^CAD	-2.94%		-2.94%	-50.75%

Apr. 25	Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI
Apr. 25	Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

APTE BIOS : Material Agreement - Form 8-K	Apr. 26	PU
APTE BIOS : Aptose Corporate Presentation April 2024	Apr. 24	PU
Aptose Reports Results for the Fourth Quarter and Full Year 2023	Mar. 26	AQ
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024	Mar. 18	AQ
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option	Jan. 31	AQ
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical	Jan. 26	AQ
APTE BIOS : Aptose Corporate Presentation December 2023	Dec. 26	PU
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting	Dec. 09	AQ
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role	Nov. 30	AQ
Aptose Biosciences: Q3 Earnings Snapshot	Nov. 09	AQ
Aptose Reports Results for the Third Quarter 2023	Nov. 09	AQ
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting	Nov. 02	AQ
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib	23-10-30	AQ
APTE BIOS : 2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax	23-10-29	PU
APTE BIOS : 2023 ESH Poster – Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)	23-10-29	PU
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023	23-10-26	AQ
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th	23-10-23	AQ
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference	23-10-16	AQ
Aptose to Present at the Cantor Global Healthcare Conference	23-09-18	AQ
APTE BIOS : Aptose Corporate Presentation September 2023	23-09-11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Press Releases

Filters